The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans

British Journal of Clinical Pharmacology

Volumn 68, Issue 4, 2009, Pages 518-523

  Cheriyan, Joseph ^a   Burton, Timothy J ^a   Bradley, Timothy J ^b   Wallace, Sharon M L ^a   Mäki Petäjä, Kaisa M ^a   MacKenzie, Isla S ^a   McEniery, Carmel M ^a   Brown, John ^a   Wilkinson, Ian B ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Forearm blood flow; Haemodynamics; Urantide; Urotensin II

Indexed keywords

URANTIDE; UROTENSIN II;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; FOREARM BLOOD FLOW; HEART RATE; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADULT; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FOREARM; HEART RATE; HEMODYNAMICS; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; PEPTIDE FRAGMENTS; REGIONAL BLOOD FLOW; TREATMENT OUTCOME; UROTENSINS; YOUNG ADULT;

EID: 70449112887     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03475.x     Document Type: Article

References (27)

1. Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS, Bern HA. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 1980 77 : 5021 5024.
2. Bern HA, Pearson D, Larson BA, Nishioka RS. Neurohormones from fish tails: the caudal neurosecretory system. I. 'Urophysiology' and the caudal neurosecretory system of fishes. Recent Prog Horm Res 1985 41 : 533 552.
3. Itoh H, Itoh Y, Rivier J, Lederis K. Contraction of major artery segments of rat by fish neuropeptide urotensin II. Am J Physiol 1987 252 : R361 6.
4. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, Vaudry H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 1998 95 : 15803 15808.
5. Elshourbagy NA, Douglas SA, Shabon U, Harrison S, Duddy G, Sechler JL, Ao Z, Maleeff BE, Naselsky D, Disa J, Aiyar NV. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 2002 136 : 9 22.
6. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999 401 : 282 286.
7. Marchese A, Heiber M, Nguyen T, Heng HH, Saldivia VR, Cheng R, Murphy PM, Tsui LC, Shi X, Gregor P. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics 1995 29 : 335 344.
8. Tal M, Ammar DA, Karpuj M, Krizhanovsky V, Naim M, Thompson DA. A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia. Biochem Biophys Res Commun 1995 209 : 752 759.
9. Maguire JJ, Davenport AP. Is urotensin-II the new endothelin? Br J Pharmacol 2002 137 : 579 588.
10. Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000 131 : 441 446.
11. Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, Kirk A, Richardson M, MacLean MR. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 2001 280 : H925 8.
12. Leslie SJ, Denvir M, Webb DJ. Human urotensin II causes vasoconstriction in the human skin microcirculation. Circulation 2001 102 : 542.
13. Sondermeijer B, Kompa A, Komesaroff P, Krum H. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 2005 18 : 1195 1199.
14. Rossi M, Magagna A, Di Maria C, Franzoni F, Taddei S, Santoro G. Skin vasodilator effect of exogenous urotensin-II in hypertensives not exposed to antihypertensive medication. Blood Press 2008 17 : 18 25.
15. Kemp W, Roberts S, Komesaroff PA, Zomer E, Krum H. Urotensin II in chronic liver disease: in vivo effect on vascular tone. Scand J Gastroenterol 2008 43 : 103 109.
16. Bohm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002 135 : 25 7.
17. Wilkinson IB, Affolter JT, de Haas SL, Pellegrini MP, Boyd J, Winter MJ, Balment RJ, Webb DJ. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 2002 53 : 341 347.
18. Patacchini R, Santicioli P, Giuliani S, Grieco P, Novellino E, Rovero P, Maggi CA. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br J Pharmacol 2003 140 : 1155 1158.
19. O'Brien E, Mee F, Atkins N, Thomas M. Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. Blood Press Monit 1996 1 : 55 61.
20. Wilkinson IB, Webb DJ. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol 2001 52 : 631 646.
21. Affolter JT, Newby DE, Wilkinson IB, Winter MJ, Balment RJ, Webb DJ. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol 2002 54 : 617 621.
22. Brailoiu E, Jiang X, Brailoiu GC, Yang J, Chang JK, Wang H, Dun NJ. State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells. Peptides 2008 29 : 721 726.
23. Yano K, Hicks JW, Vaudry H, Conlon JM. Cardiovascular actions of frog urotensin II in the frog, Rana catesbeiana. Gen Comp Endocrinol 1995 97 : 103 110.
24. Watson AM, Lambert GW, Smith KJ, May CN. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 2003 42 : 373 379.
25. Bousette N, Pottinger J, Ramli W, Ohlstein EH, Dhanak D, Douglas SA, Giaid A. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 2006 27 : 2919 2926.
26. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003 93 : 246 253.
27. Camarda V, Song W, Marzola E, Spagnol M, Guerrini R, Salvadori S, Regoli D, Thompson JP, Rowbotham DJ, Behm DJ, Douglas SA, Calo G, Lambert DG. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol 2004 498 : 83 6.